Dr Reddy’s Laboratories has called back its anti-depression drug Citalopram from the US market, as it has received complaints of a strong odor. It makes 50% its revenues from the US business, where it sells a variety of products, including Para IV filings targeting patented drugs and various low-competition products. The drug maker has recalled this drug with the knowledge of the US Food and Drug Administration (USFDA) and there will be no material financial impact from it.
Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.
